GLYCOMIMETICS INC
For the period ended Jun 13, 2025. Filed Jun 18, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 13, 2025 · Filed Jun 18, 2025
Use the contents to explore the available documents and sections.
CBIO$13.54+4.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Reference:
Reference:
| 1. | Xiong, Anwen et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. The Lancet, 2025; 405 (10481); 839-849. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.